

Supplementary materials

Suppressing effect of Na⁺/Ca²⁺ exchanger (NCX) inhibitors on the growth of melanoma cells

Zi-Kai Liu [#], Qing Cheng [#], Xiao-Li Ma and Mingke Song ^{*}

Department of Pharmacology and Chemical Biology, Institute of Medical Sciences, Shanghai Jiao Tong University School of Medicine, 280 South Chongqing Road, Shanghai, 200025, China

^{*} Correspondence: Corresponding author: Mingke Song, PhD; Associate Professor; mksong@sjtu.edu.cn

[#] These authors contributed equally to this work.

This PDF document contains:

Supplementary Figure S1

Supplementary Figure S2

Supplementary Figure S3

S1. Three-dimensional (3D) cell culture and treatment




Figure S1. 3D culture of melanoma A2058 cells and treatment with bepridil. (A-B) A2058 cells were cultured in a hydrogel-based 3D cell culture platform and treated with vehicle (DMSO, 1/1000, v/v) or bepridil (25 μ M) for 48 hours. (C) Viability of A2058 cells were reduced by bepridil to 50% of vehicle-treated control level. * $P < 0.05$, bepridil treated groups vs. vehicle treatment, unpaired Student's t -test; $n = 3$ independent experiments.

S2. Western blotting data




Figure S2. Western blotting analysis of NCX1, NCX2 and NCX3 isoforms in HEM-L, HSF, A375, A2058 and C8161 cell lines. (A-C) Three times of independent western blotting results.

S3. Western blotting analysis and cell viability test




Figure S3. Western blotting analysis of samples from eight different cell lines. (A-C) The NCX1 isoform expressed in human epidermal melanocytes-light (HEM-L) and human melanoma cell lines SK-MEL-2, SK-MEL-28, WM-115, A875, A375, A2058 and C8161. (D) Quantification of the NCX1 obtained by western blotting. * $P < 0.05$, ** $P < 0.01$, each cell line compared with HEM-L; one-way ANOVA followed by a Tukey's post-hoc test, $n=3$. (E) Viability of A875, WM-115 and SK-MEL-28 cell lines after exposed to the NCX blocker bepridil for 48 hours, $n = 3$ independent experiments for each cell line.